Publications

Molecular cell

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

18-11-2021

Cell

P-stalk ribosomes act as master regulators of cytokine-mediated processes.

14-10-2024

Nucleic acids research

ADARp150 counteracts whole genome duplication.

23-09-2024

Nucleic acids research

Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing.

27-08-2024

Cancer discovery

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.

01-07-2024

Nature communications

Widespread chromatin context-dependencies of DNA double-strand break repair proteins.

22-06-2024

Cell reports. Medicine

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.

19-03-2024

The EMBO journal

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.

01-03-2024

EMBO molecular medicine

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

07-12-2023

Molecular cell

Locus-specific proteome decoding reveals Fpt1 as a chromatin-associated negative regulator of RNA polymerase III assembly.

07-12-2023

Nucleic acids research

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.

13-10-2023

Molecular oncology

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.

01-06-2023

Cell reports

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

30-05-2023

Breast cancer research : BCR

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.

05-05-2023

Cancer immunology research

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

03-04-2023

Journal of experimental & clinical cancer research : CR

Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.

03-03-2023

Haematologica

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.

01-03-2023

Cell reports. Medicine

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.

21-02-2023

Proceedings of the National Academy of Sciences of the United States of America

Mammalian life depends on two distinct pathways of DNA damage tolerance.

24-01-2023

EBioMedicine

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.

01-01-2023

Molecular cancer therapeutics

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.

02-12-2022

Bio-protocol

An Unbiased CRISPR-Cas9 Screening Method for the Identification of Positive and Negative Regulatory Proteins of Cell Adhesion.

05-11-2022

Nature cancer

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.

01-11-2022

Nature communications

A doxycycline- and light-inducible Cre recombinase mouse model for optogenetic genome editing.

28-10-2022

PloS one

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

07-09-2022

Life science alliance

Genetic and compound screens uncover factors modulating cancer cell response to indisulam.

01-09-2022

Nucleic acids research

Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.

22-07-2022

Nature communications

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.

19-04-2022

Cancers

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

16-12-2021

Genome medicine

Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.

18-10-2021

Molecular cancer research : MCR

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen.

01-10-2021

Cell reports

The Cancer SENESCopedia: A delineation of cancer cell senescence.

27-07-2021

Nature communications

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

16-07-2021

Nature

EGFR activation limits the response of liver cancer to lenvatinib.

01-07-2021

Scientific reports

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

01-07-2021

EBioMedicine

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities.

01-07-2021

Molecular cell

Impact of chromatin context on Cas9-induced DNA double-strand break repair pathway balance.

20-05-2021

Genome medicine

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

10-02-2021

eLife

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.

05-10-2020

Life science alliance

The RECQL helicase prevents replication fork collapse during replication stress.

01-10-2020

Gut

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.

01-04-2020

Nature cancer

Old drugs with new tricks.

01-02-2020

European journal of immunology

High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells.

01-01-2020

eLife

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

19-12-2019

Nature

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

01-10-2019

Cancer research

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.

01-06-2019

The Journal of experimental medicine

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

03-12-2018

Genome medicine

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

27-11-2018

Journal of hepatology

Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

01-11-2018

Oncogene

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

01-08-2018

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

P-stalk ribosomes act as master regulators of cytokine-mediated processes.

ADARp150 counteracts whole genome duplication.

Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing.

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.

Widespread chromatin context-dependencies of DNA double-strand break repair proteins.

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

Locus-specific proteome decoding reveals Fpt1 as a chromatin-associated negative regulator of RNA polymerase III assembly.

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.

Mammalian life depends on two distinct pathways of DNA damage tolerance.

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.

An Unbiased CRISPR-Cas9 Screening Method for the Identification of Positive and Negative Regulatory Proteins of Cell Adhesion.

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.

A doxycycline- and light-inducible Cre recombinase mouse model for optogenetic genome editing.

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

Genetic and compound screens uncover factors modulating cancer cell response to indisulam.

Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen.

The Cancer SENESCopedia: A delineation of cancer cell senescence.

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

EGFR activation limits the response of liver cancer to lenvatinib.

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities.

Impact of chromatin context on Cas9-induced DNA double-strand break repair pathway balance.

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.

The RECQL helicase prevents replication fork collapse during replication stress.

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.

Old drugs with new tricks.

High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells.

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

This site uses cookies